Preventive Takhzyro Now Available in Québec Following Takeda Bid Win

Takeda Canada has won a bid making it Héma-Québec’s sole source of Takhzyro (lanadelumab) — an approved under-the-skin treatment to prevent attacks of hereditary angioedema (HAE) — through at least 2024. Takhzyro is now available as a prophylaxis treatment for people with HAE in Québec, according to…

Deal Struck to Distribute Ruconest in Middle East, North Africa

Pharming Group has signed an exclusive license agreement with NewBridge Pharmaceuticals to distribute and commercialize Ruconest (conestat alfa), a treatment for acute attacks of hereditary angioedema (HAE), in the Middle East and North Africa. Under the agreement terms, NewBridge in collaboration with Pharming, will provide access…